Connect Stock Analysis

CNTB -  USA Stock  

USD 0.91  0.02  2.25%

The big decline in price over the last few months for Connect Biopharma could raise concerns from investors as the firm is trading at a share price of 0.91 on slow start in volume. The company directors and management failed to add value to investors and position the firm supply of money to exploit market volatility in April. However, diversifying your holdings with Connect Biopharma Holdings or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 12.25. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Connect Biopharma partners.
Continue to Trending Equities.
The Connect Biopharma stock analysis report makes it easy to digest most publicly released information about Connect Biopharma and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Connect Stock analysis module also helps to analyze the Connect Biopharma price relationship with some important fundamental indicators such as market cap and management efficiency.

Connect Stock Analysis Notes

About 14.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.02. Some equities with similar Price to Book (P/B) outperform the market in the long run. Connect Biopharma recorded a loss per share of 8.08. The entity had not issued any dividends in recent years. Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company was founded in 2012 and is headquartered in Taicang, China. Connect Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 108 people. For more info on Connect Biopharma Holdings please contact the company at 86 512 5357 7866 or go to

Connect Biopharma Quarterly Deferred Revenue

5 Million


Connect Biopharma Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Connect Biopharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Connect Biopharma Holdings or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Connect Biopharma generated a negative expected return over the last 90 days
Connect Biopharma has high historical volatility and very poor performance
Connect Biopharma has some characteristics of a very speculative penny stock
Net Loss for the year was (1.31 B).
Connect Biopharma Holdings currently holds about 1.71 B in cash with (544.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 31.07, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Connect Biopharma has a frail financial position based on the latest SEC disclosures
Roughly 14.0% of the company shares are held by company insiders
Latest headline from Form F-3A Connect Biopharma Holdin -

Connect Biopharma Upcoming and Recent Events

Earnings reports are used by Connect Biopharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Connect Biopharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report (could be delayed)31st of August 2021
Next Fiscal Quarter End30th of June 2021
Last Quarter Report31st of March 2021
Last Financial Announcement30th of June 2020

Connect Biopharma SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Connect Biopharma prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Connect Biopharma investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Connect Biopharma specific information freely available to individual and institutional investors to make a timely investment decision.
9th of May 2022
Other Events
5th of May 2022
Other Events
3rd of May 2022
Other Events
31st of March 2022
Other Events
1st of March 2022
Other Events
25th of February 2022
Unclassified Corporate Event
16th of February 2022
Other Events
15th of February 2022
Unclassified Corporate Event

Connect Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Connect Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Connect Biopharma Holdings backward and forwards among themselves. Connect Biopharma's institutional investor refers to the entity that pools money to purchase Connect Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Ra Capital Management LpCommon SharesM21.1 M
Fmr LlcCommon Shares2.3 M6.9 M
Blackrock IncCommon Shares2.2 M6.8 M
Janus Henderson Group PlcCommon Shares1.6 M4.8 M
Adage Capital Partners Gp LlcCommon Shares1.4 M4.3 M
Ikarian Capital LlcCommon Shares677.9 KM
Sio Capital Management LlcCommon Shares597.7 K1.8 M
Note, although Connect Biopharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Connect Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 50.39 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Connect Biopharma's market, we take the total number of its shares issued and multiply it by Connect Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Connect Profitablity

Connect Biopharma's profitability indicators refer to fundamental financial ratios that showcase Connect Biopharma's ability to generate income relative to its revenue or operating costs. If, let's say, Connect Biopharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Connect Biopharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Connect Biopharma's profitability requires more research than a typical breakdown of Connect Biopharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.89) (0.96) 
Return on Average Equity(3.68) (3.77) 
Return on Invested Capital(36.40) (39.27) 

Management Efficiency

The entity has return on total asset (ROA) of (26.72) % which means that it has lost $26.72 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (367.66) %, meaning that it created substantial loss on money invested by shareholders. Connect Biopharma management efficiency ratios could be used to measure how well connect biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of May 24, 2022, Return on Average Assets is expected to decline to -0.96. In addition to that, Return on Average Equity is expected to decline to -3.77. As of May 24, 2022, Total Assets is expected to decline to about 1.6 B. In addition to that, Current Assets is expected to decline to about 1.5 B
Last ReportedProjected for 2022
Book Value per Share 30.20  32.58 
Enterprise Value over EBITDA 0.08  0.08 
Price to Book Value 0.98  0.97 
Tangible Assets Book Value per Share 32.27  32.15 
Enterprise Value-15.5 M-16.8 M
Tangible Asset Value1.9 B1.6 B

Technical Drivers

As of the 24th of May, Connect Biopharma shows the risk adjusted performance of (0.17), and Mean Deviation of 7.06. Connect Biopharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Connect Biopharma Holdings, which can be compared to its rivals. Please confirm Connect Biopharma jensen alpha, as well as the relationship between the potential upside and skewness to decide if Connect Biopharma is priced correctly, providing market reflects its regular price of 0.91 per share. Given that Connect Biopharma is a hitting penny stock territory we recommend to closely look at its total risk alpha.

Connect Biopharma Price Movement Analysis

Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Mid-point over period is an average of Connect Biopharma highest and lowest values attained during the given period.

Connect Biopharma Predictive Daily Indicators

Connect Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Connect Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Connect Biopharma Forecast Models

Connect Biopharma time-series forecasting models is one of many Connect Biopharma's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Connect Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Connect Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Connect Biopharma stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Connect shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Connect Biopharma. By using and applying Connect Stock analysis, traders can create a robust methodology for identifying Connect entry and exit points for their positions.
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company was founded in 2012 and is headquartered in Taicang, China. Connect Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 108 people.

Current Connect Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Connect analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Connect analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
22.0Strong Buy3Odds
Connect Biopharma Holdings current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Connect analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Connect stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Connect Biopharma, talking to its executives and customers, or listening to Connect conference calls.
Connect Analyst Advice Details

Connect Stock Analysis Indicators

Connect Biopharma Holdings stock analysis indicators help investors evaluate how Connect Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Connect Biopharma shares will generate the highest return on investment. By understating and applying Connect Biopharma stock analysis, traders can identify Connect Biopharma position entry and exit signals to maximize returns.
Shares Percent Shares Out0.58%
Quick Ratio14.92
Fifty Two Week Low0.5570
Forward Price Earnings-0.42
Float Shares18.67M
Fifty Two Week High29.2740
Shares Short Prior Month284.92k
Average Daily Volume Last 10 Day632.07k
Average Daily Volume In Three Month242.1k
Enterprise Value To Ebitda2.56
Fifty Day Average2.4562
Two Hundred Day Average9.8441
Continue to Trending Equities. Note that the Connect Biopharma information on this page should be used as a complementary analysis to other Connect Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for Connect Stock analysis

When running Connect Biopharma price analysis, check to measure Connect Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Connect Biopharma is operating at the current time. Most of Connect Biopharma's value examination focuses on studying past and present price action to predict the probability of Connect Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Connect Biopharma's price. Additionally, you may evaluate how the addition of Connect Biopharma to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Is Connect Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Connect Biopharma. If investors know Connect will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Connect Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Connect Biopharma is measured differently than its book value, which is the value of Connect that is recorded on the company's balance sheet. Investors also form their own opinion of Connect Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Connect Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Connect Biopharma's market value can be influenced by many factors that don't directly affect Connect Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Connect Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Connect Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Connect Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.